2020
DOI: 10.1080/17441692.2020.1825769
|View full text |Cite
|
Sign up to set email alerts
|

Strategic use of patent opposition safeguard to improve equitable access to innovative health technologies: A case study of CAR T-cell therapy Kymriah

Abstract: Kymriah is an innovative cancer therapy which works by removing disease fighting T-cells from patients, genetically modifying or reprogramming the immune cells to attack cancer, and re-infusing them back into the patients. It treats childhood blood and bone marrow cancer. The cost of this new hope-giving gene therapy is CHF 450,000 per treatment. This exorbitantly high price set by Novartis, in exercise of its exclusive rights resulting from patent protection, undermines the real-world impact of this revolutio… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4
1

Relationship

1
4

Authors

Journals

citations
Cited by 5 publications
(3 citation statements)
references
References 11 publications
0
2
0
Order By: Relevance
“…The patent opposition procedures provided by the European Union (EU), the USA and Japan conflict with the Indian patent opposition model. The European Patent Convention (EPC) 6 provides for a supra-national post-grant third-party opposition procedure (Abbas, 2020(Abbas, , 2020b. This inter partes administrative procedure allows third parties to file a notice of opposition at the EPO within nine months after the grant of a European patent is published (Abbas, 2020b).…”
Section: Ftas and Harmonisation Demands: Challenges For Indiamentioning
confidence: 99%
See 1 more Smart Citation
“…The patent opposition procedures provided by the European Union (EU), the USA and Japan conflict with the Indian patent opposition model. The European Patent Convention (EPC) 6 provides for a supra-national post-grant third-party opposition procedure (Abbas, 2020(Abbas, , 2020b. This inter partes administrative procedure allows third parties to file a notice of opposition at the EPO within nine months after the grant of a European patent is published (Abbas, 2020b).…”
Section: Ftas and Harmonisation Demands: Challenges For Indiamentioning
confidence: 99%
“…The European Patent Convention (EPC) 6 provides for a supra-national post-grant third-party opposition procedure (Abbas, 2020(Abbas, , 2020b. This inter partes administrative procedure allows third parties to file a notice of opposition at the EPO within nine months after the grant of a European patent is published (Abbas, 2020b). 7 Any natural or legal person, other than the patent owner, may file a patent opposition.…”
Section: Ftas and Harmonisation Demands: Challenges For Indiamentioning
confidence: 99%
“…During treatment, one child experienced serious complications, but the disease was eventually steadily alleviated. In 2017, the USA Food and Drug Administration (FDA) approved two CAR-T cells targeting the CD19 protein, named Kymriah and Yescarta, for the treatment of ALL and diffuse large B-cell lymphoma, respectively, and ~83% of patients treated with Kymriah achieved a response of ≤5 years after 3 months of treatment ( 10 , 11 ). In 2020, Astolfi et al ( 12 ) published a study indicating that the inactivation of tumor suppressor genes was the primary driver of sarcomas.…”
Section: Introductionmentioning
confidence: 99%